Wirginia Krzyściak | Pharmacology, Toxicology and Pharmaceutical Science | Women Researcher Award

Posted on by ScienceFather

Dr. Wirginia Krzyściak | Pharmacology, Toxicology and Pharmaceutical Science | Women Researcher Award

Acting Head of Department of Medical Diagnostics at the Faculty of Pharmacy of the Medical College of the Jagiellonian University in Krakow, Poland 

Dr. Wirginia Krzyściak is a distinguished researcher and academic leader in the field of medical diagnostics, currently serving as the Acting Head of the Department of Medical Diagnostics at the Jagiellonian University Medical College (JU MC) in Poland. With a career spanning over a decade, she has made significant contributions to the study of schizophrenia, clinical biochemistry, and the relationship between oral microbiota and brain function 🧠. A prolific author with 85 original scientific papers and a strong h-index of 16, Dr. Krzyściak’s work is highly regarded in both national and international academic circles 🌍. She also serves on the editorial boards of several high-impact scientific journals, focusing on biostatistics, brain diseases, and biomolecules related to biofilm diseases. Beyond her research, she is actively involved in mentoring, having supervised numerous master’s and doctoral theses 🎓.

Professional profile

Education📚

Dr. Wirginia Krzyściak has a rich academic background rooted in the medical and pharmaceutical sciences. She earned her Doctoral Degree in Medical Sciences, specializing in clinical biochemistry from Jagiellonian University Medical College (JU MC) in 2009 🎓. In 2018, she achieved her habilitation in Pharmaceutical Science, a prestigious qualification marking her academic excellence and expertise. Dr. Krzyściak’s education has laid a strong foundation for her research endeavors in schizophrenia and clinical diagnostics. She has also contributed to academic literature, authoring numerous papers and chapters in textbooks 📚. Her academic qualifications are further bolstered by her active membership in several scientific societies, including the Polish Microbiology Society and the Polish Biochemistry Society. Through her education, Dr. Krzyściak has gained deep insights into the biochemical and molecular aspects of schizophrenia, positioning her as a leading researcher in her field 🔬.

Professional Experience🏛️

Dr. Wirginia Krzyściak has over a decade of professional experience in the fields of medical diagnostics and clinical biochemistry. Since 2010, she has held various academic positions at Jagiellonian University Medical College (JU MC), starting as an Assistant and later becoming an Adjunct in the Department of Medical Diagnostics 🧑‍🔬. She is currently the Acting Head of the Department, where she leads cutting-edge research on schizophrenia and biomolecular diagnostics. Beyond her academic role, Dr. Krzyściak is an expert consultant for the Central Medical Laboratory in Bytom 🏥. Her leadership extends to numerous research projects, including those focused on oral microbiota and brain function. Dr. Krzyściak is also deeply involved in mentoring, having supervised 25 master’s theses and two doctoral dissertations 🎓. Her comprehensive experience in research, diagnostics, and teaching makes her a key figure in the field of clinical biochemistry and pharmaceutical sciences.

Research Interest🌐

Dr. Wirginia Krzyściak’s research interests are centered on the intersection of clinical biochemistry, medical diagnostics, and neuroscience 🧠. She has made significant contributions to understanding the biochemical and molecular underpinnings of schizophrenia, focusing on the relationship between oral microbiota and brain function, oxidative stress, and metabolic imbalances 🧪. Her recent projects explore innovative diagnostic biomarkers, particularly in brain diseases and biofilm-related infections, which hold promise for personalized medical approaches. Additionally, Dr. Krzyściak is intrigued by the role of acid stress in central nervous system disorders and the potential therapeutic interventions targeting these pathways. As the principal investigator in multiple national and international research projects, she continues to explore the frontiers of medical diagnostics, aiming to improve individualized patient care through cutting-edge biostatistical and biochemical methodologies 🔬. Her research portfolio reflects a multidisciplinary approach, integrating pharmaceutical sciences with clinical applications for psychiatric conditions like schizophrenia.

Awards and Honors🏆

Dr. Wirginia Krzyściak has received numerous prestigious awards and honors throughout her career 🌟. In 2024, she was awarded the Rector’s Award for Scientific Achievements, recognizing her outstanding contributions to the field of medical diagnostics. The previous year, she received the Bronze Medal for Long Service, acknowledging her decade-long dedication to academia 🏅. She has also been recognized multiple times by the Faculty of Pharmacy at Jagiellonian University Medical College, receiving the Dean’s Award for Scientific Achievements in 2022. Earlier in her career, she earned the Badge of the Krakow branch of the Polish Society of Microbiologists in 2017. Dr. Krzyściak’s accomplishments are a testament to her dedication to scientific research, mentorship, and academic leadership. Her continuous commitment to advancing medical diagnostics, especially in schizophrenia research, has earned her a strong reputation in the scientific community 🧬.

Conclusion:

Dr. Wirginia Krzyściak is an outstanding candidate for the Women Researcher Award. Her extensive experience, significant contributions to schizophrenia research, and leadership roles within academia make her a strong contender. She has demonstrated scientific excellence, international collaboration, and research leadership. However, focusing more on initiatives supporting women in science and engaging more broadly with the public could enhance her profile for this specific award.

Publications top noted📜
  • From Periphery Immunity to Central Domain Through Clinical Interview as a New Insight on Schizophrenia
    Krzyściak, W., Szwajca, M., Śmierciak, N., Skalniak, A., Popiela, T.
    Scientific Reports (2024), 14(1), 5755
    🔬 Citations: 1
  • Association of Blood Metabolomics Biomarkers with Brain Metabolites and Patient-Reported Outcomes as a New Approach in Individualized Diagnosis of Schizophrenia
    Krzyściak, W., Bystrowska, B., Karcz, P., Popiela, T., Pilecki, M.
    International Journal of Molecular Sciences (2024), 25(4), 2294
    🧠 Citations: 0
  • Modified Lactoperoxidase System as a Promising Anticaries Agent: In Vitro Studies on Streptococcus mutans Biofilms
    Magacz, M., Alatorre-Santamaría, S., Kędziora, K., Pamuła, E., Krzyściak, W.
    International Journal of Molecular Sciences (2023), 24(15), 12136
    🦷 Citations: 1
  • Benefits and Meaning of Lipids Profile in Relation to Oxidative Balance and Brain Morphology in Schizophrenia
    Śmierciak, N., Krzyściak, W., Szwajca, M., Aleksandrovych, V., Pilecki, M.
    International Journal of Molecular Sciences (2023), 24(14), 11375
    🧬 Citations: 3
  • The Association of the Oral Microbiota with the Effects of Acid Stress Induced by an Increase of Brain Lactate in Schizophrenia Patients
    Krzyściak, W., Karcz, P., Bystrowska, B., Popiela, T.J., Pilecki, M.
    Biomedicines (2023), 11(2), 240
    🧫 Citations: 4
  • Safety Assessment of the Modified Lactoperoxidase System—In Vitro Studies on Human Gingival Fibroblasts
    Magacz, M., Papież, M., Kościelniak, D., Pamuła, E., Krzyściak, W.
    International Journal of Molecular Sciences (2023), 24(3), 2640
    🧪 Citations: 2
  • Risk Factors for Weight Gain in Patients with First-Episode Psychosis
    Batko, B., Szwajca, M., Śmierciak, N., Turek, A., Pilecki, M.
    Psychiatria Polska (2023), 57(1), pp. 51–64
    🏋️ Citations: 1
  • Immunological Routine Laboratory Parameters at Admission Influence the Improvement of Positive Symptoms in Schizophrenia Patients After Pharmacological Treatment
    Skalniak, A., Krzyściak, W., Śmierciak, N., Kozicz, T., Pilecki, M.
    Frontiers in Psychiatry (2023), 14, 1082135
    💊 Citations: 4
  • Effect of a Short-Term Intervention with Lactobacillus salivarius Probiotic on Early Childhood Caries—An Open Label Randomized Controlled Trial
    Staszczyk, M., Jamka-Kasprzyk, M., Kościelniak, D., Krzyściak, W., Jurczak, A.
    International Journal of Environmental Research and Public Health (2022), 19(19), 12447
    👶 Citations: 11

Kyu Min Kim | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Kyu Min Kim | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Associate Professor at Chosun University, South Korea

Dr. Kyu Min Kim, born on July 13, 1984, is an Associate Professor at the Laboratory of Translational Genetics, Department of Biomedical Science, College of Natural Science, Chosun University, Korea. He also holds a position as a registered pharmacist in the Republic of Korea. 📅🏫

Professional profile

Education📚

Dr. Kim completed his Ph.D. in Pharmacy with a focus on Molecular Pharmacology at Seoul National University (2011-2018), where he investigated antifibrotic targets in hepatic stellate cells. He obtained his M.S. in Pharmacy from Chosun University (2007-2009) and his B.S. in Pharmacy from the same institution (2003-2007). 🎓📚

Professional Experience🏛️

Dr. Kim has extensive experience in academia and research. He served as a Teaching and Research staff at Chosun University (Mar 2018 – Feb 2021) and as a researcher at several institutes, including the Research Institute of Pharmaceutical Science at Chosun University and Seoul National University. His career also includes experience as a pharmacist at Chonnam National University Hospital. 🏥🔬

Research Interest🌐

His research interests span molecular pharmacology, liver pathophysiology, and antifibrotic mechanisms. Dr. Kim focuses on hepatic stellate cell activation, liver fibrosis, and cellular responses to oxidative stress, aiming to understand and address complex biological and therapeutic challenges. 🔬💉

Awards and Honors🏆

Dr. Kim has received several accolades for his work, including the Excellent Paper Award at the 2nd China Chemical Looping Conference (2023), recognition as an Outstanding Graduate Student in Shanghai (2022), and the National Scholarship of the People’s Republic of China (2021). These honors underscore his significant contributions to his field. 🏆🎖️

Achievements🏅
  • Innovative Research Contributions:
    • Developed novel insights into hepatic stellate cell activation and antifibrotic targets, enhancing understanding of liver fibrosis mechanisms. 🔬🧬
    • Investigated the role of sphingosine kinase in liver pathophysiology, providing a deeper comprehension of liver-related diseases. 🌟🧪
  • Academic and Research Excellence:
    • Awarded the Excellent Paper of the 2nd China Chemical Looping Conference (2023). 🏅🔬
    • Recognized as an Outstanding Graduate Student in Shanghai (2022). 🏆🎓
    • Received the National Scholarship of the People’s Republic of China (2021). 🎖️🌍
  • Professional Impact:
    • Significant contributions to molecular pharmacology through various research roles at Chosun University and Seoul National University. 💼🏥
    • Actively involved in advancing pharmacological research and education in his field. 📈👨‍🏫
Publications top noted📜
  • Parkin-Mediated Mitophagy by TGF-β Is Connected with Hepatic Stellate Cell Activation
    • Authors: Lee, J.H., Kim, K.M.*, Jung, E.H., Cho, S.S., Ki, S.H.
    • Journal: International Journal of Molecular Sciences
    • Year: 2023
    • Citations: 2 📄🔬
  • Integrative Roles of Sphingosine Kinase in Liver Pathophysiology
    • Authors: Kim, K.M.*, Shin, E.J., Yang, J.H., Ki, S.H.
    • Journal: Toxicological Research
    • Year: 2023
    • Citations: 4 🧬🔍
  • Identification of Histone Lysine Acetoacetylation as a Dynamic Post-Translational Modification Regulated by HBO1
    • Authors: Gao, Y., Sheng, X., Tan, D., Zhao, Y., Lee, S., Kim, K.M
    • Journal: Advanced Science
    • Year: 2023
    • Citations: 2 📚✨
  • Protective Effect of Castanopsis sieboldii Extract against UVB-Induced Photodamage in Keratinocytes
    • Authors: Lee, H.R., Yang, J.H., Lee, J.H., Kim, K.M., Shin, H.-J., Ki, S.H.
    • Journal: Molecules
    • Year: 2023
    • Citations: 3 🌿🛡️
  • Ferroptosis Contributes to Hepatic Stellate Cell Activation and Liver Fibrogenesis
    • Authors: Cho, S.S., Yang, J.H., Lee, J.H., Kim, K.M*, Ki, S.H.
    • Journal: Free Radical Biology and Medicine
    • Year: 2022
    • Citations: 15 🩸⚠️
  • Regulated in Development and DNA Damage Response 1 Protects Hepatocytes Against Palmitate-Induced Lipotoxicity
    • Authors: Kim, J.H., Kim, K.M*, Yang, J.H., Lee, J.H., Ki, S.H.
    • Journal: Biotechnology and Bioprocess Engineering
    • Year: 2022
    • Citations: 0 🛡️🔬
  • Characterization of Hyperglycemia Due to Sub-Chronic Administration of Red Ginseng Extract via Comparative Global Proteomic Analysis
    • Authors: Na, A.-Y., Jo, J.J., Kwon, O.K., Kim, J.H., Kim, K.M, Ki, S.H., Lee, S.
    • Journal: Scientific Reports
    • Year: 2021
    • Citations: 3 🌱🔬
  • REDD1 Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis via Inhibiting the TGF-β/Smad Signaling Pathway
    • Authors: Cho, S.S., Lee, J.H., Kim, K.M*, Yang, J.H., Ki, S.H.
    • Journal: Free Radical Biology and Medicine
    • Year: 2021
    • Citations: 21 🌟💡
  • Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance
    • Authors: Park, M., Kim, J.W., Kim, K.M*, Cho, Y., Lee, H., Baek, M.C., et al.
    • Journal: Cancer Research
    • Year: 2021
    • Citations: 13 🦠🚀
  • Transforming Growth Factor Beta-Induced FoxO3a Acts as a Profibrotic Mediator in Hepatic Stellate Cells
    • Authors: Kim, S.J., Kim, K.M*, Yang, J.H., Park, E.Y., Ki, S.H.
    • Journal: Toxicological Sciences
    • Year: 2021
    • Citations: 4 🔬🔄

Ismail Tuncer Degim | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Dr. Ismail Tuncer Degim | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Prof. of Biruni University, Faculty of Pharmacy, Turkey

Ismail Tuncer DEGIM 🎓, born on 17 February 1963, is a distinguished professor in pharmaceutical sciences with a robust educational background, including a Ph.D. from the University of Wales, Cardiff. His career at Gazi University and Biruni University has seen him rise from Research Assistant to Dean 👨‍🏫. With numerous patents to his name, including innovations in drug delivery systems 💊, Dr. DEGIM has significantly impacted community health. His leadership roles, editorial board memberships 📚, and consultancy for Turkey’s Health Ministry underscore his commitment to advancing pharmaceutical research and education. His work not only enhances scientific understanding but also brings practical healthcare solutions to communities, making him a deserving candidate for the Research for Community Impact Award 🏆.

Professional profile

Education:
  • Graduate: Faculty of Pharmacy, Ankara University, 1985
  • Master: Faculty of Pharmacy / Pharmaceutical Technology, Gazi University, 1988
  • PhD: The School of Pharmacy, University of Wales, Cardiff, UK, 1996
Professional Titles and Roles:
  • Research Assistant: Gazi University, Faculty of Pharmacy, Ankara, Turkey (1985-1996)
  • Dr. Research Assistant: Gazi University, Faculty of Pharmacy, Ankara, Turkey (1996-1996)
  • Dr. Second Lieutenant: M.S.B. Army Drug Factory, Ankara, Turkey (1996-1998)
  • Assistant Professor: Gazi University, Faculty of Pharmacy, Ankara, Turkey (1998-2004)
  • Associate Professor: Gazi University, Faculty of Pharmacy, Ankara, Turkey (2004-2009)
  • Professor: Gazi University, Faculty of Pharmacy, Ankara, Turkey (2009-)
  • Vice Dean: Gazi University, Faculty of Pharmacy, Ankara, Turkey (2010-2012)
  • Dean: Gazi University, Faculty of Pharmacy, Ankara, Turkey (2012-2016)
  • Vice Dean: Biruni University, Faculty of Pharmacy, Istanbul, Turkey (2016-2019)
  • Dean: Biruni University, Faculty of Pharmacy, Istanbul, Turkey (2020-)
Consultancy and Committee Memberships:
  • Consultant: Health of Ministry, Drug Licensing office (1999-2019)
  • Committee Member: The Scientific And Technological Research Council Of Turkey (2008-2012)
  • Evaluator: Higher Education Institution of Turkey (YÖK), Quality Board (2017-)
Patents:
  1. Method for measuring blood urea level by reverse iontophoresis (US7231242, EP1526891, AT480296, CN100431641)
  2. Hemodialysis cartridge (US8057680, RU2323015, TR200401118, CN100518837)
  3. Extended release fluvastatin tablet (TR200800634)
  4. Swallable Iontophoresis tablet (TR201720318A2)
Editorial Board Memberships:
  • Hacettepe University Journal of the Faculty of Pharmacy: 2006-2014
  • Journal of Biophysical Chemistry: 2010-2017
  • Asian Chemistry Letters: 2011-
  • Türkiye klinikleri, Eczacılık Bilimleri: 2011-
  • Austin Chromatography: 2014-
  • ACTA Pharmaceutica Sciencia: 2017-
  • Pharmaceutical Drug Regulatory Affairs Journal: 2018-
  • Bırunı Health And Educatıon Scıences Journal: 2017-
  • Pharmaceutical Science and Technology: 2018-
  • Current Drug Delıvery: 2023-
Evaluation for the Research for Community Impact Award:

Research Contributions: Dr. Ismail Tuncer DEGIM has made significant contributions to pharmaceutical sciences, particularly in drug delivery systems and pharmaceutical technology. His research spans various innovative methods and technologies that directly impact community health.

  1. Patents and Innovations:
    • His patents on measuring blood urea levels and hemodialysis cartridges have practical applications in improving diagnostic and treatment methods, benefiting patients with kidney issues and those requiring dialysis.
    • The development of extended-release tablets and iontophoresis tablets demonstrates his work on advanced drug delivery systems, which improve patient compliance and therapeutic efficacy.
  2. Leadership and Mentorship:
    • Dr. DEGIM has held numerous leadership positions, including Dean at multiple universities, where he has influenced the direction of pharmaceutical education and research.
    • His roles in consultancy and evaluation for health and educational institutions show his commitment to improving standards and practices in pharmaceutical sciences and healthcare.
  3. Editorial and Scholarly Contributions:
    • Serving on the editorial boards of various scientific journals, Dr. DEGIM has contributed to the dissemination and critical evaluation of pharmaceutical research, enhancing the quality and impact of published work.

Impact on Community: Dr. DEGIM’s work has a tangible impact on community health through the development of better diagnostic tools, improved drug delivery systems, and effective treatments. His research addresses critical healthcare needs, from chronic kidney disease management to innovative drug formulations, making his contributions invaluable to public health.

Conclusion: Dr. Ismail Tuncer DEGIM is a strong candidate for the Research for Community Impact Award. His extensive research portfolio, leadership in pharmaceutical education, and commitment to practical healthcare solutions demonstrate his significant contributions to improving community health and wellbeing. His innovative work and dedication to advancing pharmaceutical sciences make him an exemplary researcher deserving of recognition for his impact on the community.

Publications top noted📜
  • Controlled delivery of peptides and proteins 💊
    • Authors: I Tuncer Degim, N Celebi
    • Journal: Current Pharmaceutical Design
    • Year: 2007
    • Citations: 215
  • Epidermal permeability–penetrant structure relationships: 4, QSAR of permeant diffusion across human stratum corneum in terms of molecular weight, H-bonding and electronic charge 🔬
    • Authors: WJ Pugh, IT Degim, J Hadgraft
    • Journal: International Journal of Pharmaceutics
    • Year: 2000
    • Citations: 129
  • New tools and approaches for predicting skin permeability 🛠️
    • Authors: IT Degim
    • Journal: Drug Discovery Today
    • Year: 2006
    • Citations: 101
  • Prediction of skin penetration using artificial neural network (ANN) modeling 🤖
    • Authors: T Değim, J Hadgraft, S İlbasmiş, Y Özkan
    • Journal: Journal of Pharmaceutical Sciences
    • Year: 2003
    • Citations: 91
  • Skin permeability data: anomalous results 📊
    • Authors: IT Degim, WJ Pugh, J Hadgraft
    • Journal: International Journal of Pharmaceutics
    • Year: 1998
    • Citations: 88
  • Anti-aging formulation of rosmarinic acid-loaded ethosomes and liposomes 🧴
    • Authors: Ç Yücel, G Şeker Karatoprak, İT Değim
    • Journal: Journal of Microencapsulation
    • Year: 2019
    • Citations: 76
  • Carbon nanotubes for transdermal drug delivery 🌐
    • Authors: IT Degim, DJ Burgess, F Papadimitrakopoulos
    • Journal: Journal of Microencapsulation
    • Year: 2010
    • Citations: 75
  • Carbon nanotubes to deliver drug molecules 💊
    • Authors: S Ilbasmiş-Tamer, Ş Yilmaz, E Banoğlu, IT Değim
    • Journal: Journal of Biomedical Nanotechnology
    • Year: 2010
    • Citations: 75
  • Rapid and simultaneous determination of acetylsalicylic acid, paracetamol, and their degradation and toxic impurity products by HPLC in pharmaceutical dosage forms 🧪
    • Authors: C Akay, İT Değim, A Sayal, A Aydin, Y Özkan, H Gül
    • Journal: Turkish Journal of Medical Sciences
    • Year: 2008
    • Citations: 72
  • The effects of Azone and capsaicin on the permeation of naproxen through human skin 🧴
    • Authors: IT Degim, A Uslu, J Hadgraft, T Atay, C Akay, S Cevheroglu
    • Journal: International Journal of Pharmaceutics
    • Year: 1999
    • Citations: 68
  • Reverse iontophoresis: a non-invasive technique for measuring blood urea level 🔬
    • Authors: IT Degim, S Ilbasmis, R Dundaroz, Y Oguz
    • Journal: Pediatric Nephrology
    • Year: 2003
    • Citations: 64

 

Shaobo Ruan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Prof. Shaobo Ruan | Pharmacology, Toxicology and Pharmaceutical Science | Best Researcher Award

Associate Professor of Beijing Institute of Technology, China

Prof. Shaobo Ruan 🌟 is a distinguished academic with a focus on Pharmaceutics and Bioengineering. He earned his Ph.D. and M.D. in Pharmaceutics from the West China School of Pharmacy, Sichuan University 🎓, where he was mentored by Professors Huile Gao and Qin He. He also holds a B.S. in Pharmaceutics from Wannan Medical College. Prof. Ruan’s career includes significant roles as an Associate Professor at the Advanced Research Institute of Multidisciplinary Science 🏛️, Beijing Institute of Technology, and as a Postdoctoral Associate at the University of Florida and the University of Kansas 🔬. His research and academic pursuits have made notable contributions to the field of Pharmaceutics and Bioengineering, emphasizing interdisciplinary approaches and advanced scientific inquiry.

Professional profile

Education📚

Prof. Shaobo Ruan 🎓 has an impressive educational background in Pharmaceutics. He completed his Ph.D. in Pharmaceutics at West China School of Pharmacy, Sichuan University (2015-2018) 🏫, under the guidance of Professors Huile Gao and Qin He. Prior to that, he earned his M.D. in Pharmaceutics from the same institution (2012-2015) 🏥. His foundational studies were completed with a B.S. in Pharmaceutics from Wannan Medical College (2008-2012) 🎓.

Professional Experience🏛️

Prof. Shaobo Ruan 🌟 has built a notable career in the field of Pharmaceutics and Bioengineering. He is currently serving as an Associate Professor at the Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology 🏛️ since September 2021. Previously, he was a Postdoctoral Associate in Pharmaceutics at the University of Florida 🎓 from July 2020 to July 2021. He also held a Postdoctoral Associate position in Bioengineering at the University of Kansas 🔬 from July 2018 to June 2021. His roles have significantly contributed to advancements in his field, integrating research and interdisciplinary approaches.

Research Interest🌐

Prof. Shaobo Ruan 🔬 is deeply engaged in research that bridges Pharmaceutics and Bioengineering. His interests focus on the development and optimization of pharmaceutical formulations, drug delivery systems, and bioengineering applications 🌟. Prof. Ruan explores innovative methods to enhance drug efficacy and safety, integrating advanced technologies and interdisciplinary approaches to address complex challenges in the field. His work aims to advance therapeutic solutions and improve patient outcomes, making significant contributions to both scientific research and practical applications in Pharmaceutics and Bioengineering.

Awards and Honors🏆

Prof. Shaobo Ruan 🌟 has received notable recognition for his contributions to Pharmaceutics and Bioengineering. His excellence in research and academic achievements have earned him prestigious awards and honors 🏅. These accolades reflect his significant impact on the field, highlighting his dedication to advancing pharmaceutical sciences and bioengineering innovations. Prof. Ruan’s commitment to research and education continues to be acknowledged through various awards, underscoring his role as a leading figure in his discipline. 🏆✨

Achievements🏅
  • Ph.D. in Pharmaceutics from West China School of Pharmacy, Sichuan University 🎓
  • M.D. in Pharmaceutics from West China School of Pharmacy, Sichuan University 🏥
  • B.S. in Pharmaceutics from Wannan Medical College 🎓
  • Associate Professor at the Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology 🏛️
  • Postdoctoral Associate at the University of Florida and University of Kansas 🔬
  • Advanced pharmaceutical formulations and drug delivery systems 🌟
  • Notable contributions to Bioengineering and interdisciplinary research ✨
  • Recognition through prestigious awards and honors 🏆
Projects🛠️
  • Development of Advanced Drug Delivery Systems 💉: Innovating methods to enhance the efficacy and safety of pharmaceutical formulations.
  • Optimization of Pharmaceutical Formulations 💊: Improving drug stability, release profiles, and therapeutic outcomes.
  • Bioengineering Applications in Pharmaceutics 🌟: Integrating bioengineering techniques to address complex pharmaceutical challenges.
  • Interdisciplinary Research Initiatives 🔍: Collaborating across fields to advance research in Pharmaceutics and Bioengineering.
  • Innovative Drug-Device Combination Products 💡: Designing and evaluating novel drug delivery systems that combine pharmaceuticals with medical devices.
Publications top noted📜
  • Self-targeting fluorescent carbon dots for diagnosis of brain cancer cells
    📄 Authors: M Zheng, S Ruan, S Liu, T Sun, D Qu, H Zhao, Z Xie, H Gao, X Jing, Z Sun
    🏆 Journal: ACS Nano
    📅 Year: 2015
    🔍 Citations: 504
  • Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles
    📄 Authors: S Ruan, M Yuan, L Zhang, G Hu, J Chen, X Cun, Q Zhang, Y Yang, Q He, …
    🏆 Journal: Biomaterials
    📅 Year: 2015
    🔍 Citations: 365
  • Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release
    📄 Authors: S Ruan, X Cao, X Cun, G Hu, Y Zhou, Y Zhang, L Lu, Q He, H Gao
    🏆 Journal: Biomaterials
    📅 Year: 2015
    🔍 Citations: 280
  • Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
    📄 Authors: R Liu, C Luo, Z Pang, J Zhang, S Ruan, M Wu, L Wang, T Sun, N Li, L Han, …
    🏆 Journal: Chinese Chemical Letters
    📅 Year: 2023
    🔍 Citations: 271
  • Enzyme-triggered size shrink and laser-enhanced NO release nanoparticles for deep tumor penetration and combination therapy
    📄 Authors: C Hu, X Cun, S Ruan, R Liu, W Xiao, X Yang, Y Yang, C Yang, H Gao
    🏆 Journal: Biomaterials
    📅 Year: 2018
    🔍 Citations: 248
  • Increased Gold Nanoparticle Retention in Brain Tumors by in Situ Enzyme-Induced Aggregation
    📄 Authors: S Ruan, C Hu, X Tang, X Cun, W Xiao, K Shi, Q He, H Gao
    🏆 Journal: ACS Nano
    📅 Year: 2016
    🔍 Citations: 243
  • Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma
    📄 Authors: S Ruan, Q He, H Gao
    🏆 Journal: Nanoscale
    📅 Year: 2015
    🔍 Citations: 174
  • Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment
    📄 Authors: S Ruan, R Xie, L Qin, M Yu, W Xiao, C Hu, W Yu, Z Qian, L Ouyang, Q He, …
    🏆 Journal: Nano Letters
    📅 Year: 2019
    🔍 Citations: 151
  • A novel strategy through combining iRGD peptide with tumor-microenvironment-responsive and multistage nanoparticles for deep tumor penetration
    📄 Authors: X Cun, J Chen, S Ruan, L Zhang, J Wan, Q He, H Gao
    🏆 Journal: ACS Applied Materials & Interfaces
    📅 Year: 2015
    🔍 Citations: 136
  • Acid‐responsive transferrin dissociation and GLUT mediated exocytosis for increased blood–brain barrier transcytosis and programmed glioma targeting delivery
    📄 Authors: S Ruan, L Qin, W Xiao, C Hu, Y Zhou, R Wang, X Sun, W Yu, Q He, H Gao
    🏆 Journal: Advanced Functional Materials
    📅 Year: 2018
    🔍 Citations: 131
  • Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization
    📄 Authors: S Ruan, Y Zhou, X Jiang, H Gao
    🏆 Journal: Advanced Science
    📅 Year: 2021
    🔍 Citations: 120
  • A dual strategy to improve the penetration and treatment of breast cancer by combining shrinking nanoparticles with collagen depletion by losartan
    📄 Authors: X Cun, S Ruan, J Chen, L Zhang, J Li, Q He, H Gao
    🏆 Journal: Acta Biomaterialia
    📅 Year: 2016
    🔍 Citations: 118
  • A simple one-step method to prepare fluorescent carbon dots and their potential application in non-invasive glioma imaging
    📄 Authors: S Ruan, J Qian, S Shen, J Zhu, X Jiang, Q He, H Gao
    🏆 Journal: Nanoscale
    📅 Year: 2014
    🔍 Citations: 116